{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:43:41Z","timestamp":1769636621610,"version":"3.49.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011781","name":"Shriners Hospitals for Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 ES015988"],"award-info":[{"award-number":["R01 ES015988"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 NS059043"],"award-info":[{"award-number":["R01 NS059043"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.expneurol.2011.04.021","type":"journal-article","created":{"date-parts":[[2011,5,7]],"date-time":"2011-05-07T21:12:30Z","timestamp":1304802750000},"page":"227-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia"],"prefix":"10.1016","volume":"230","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer M.","family":"Plane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Pleasure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2011.04.021_bb0005","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1460-9568.1996.tb01278.x","article-title":"Reversible inhibitory effects of interferon-\u03b3 and tumor necrosis factor-\u03b1 on oligodendroglial lineage cell proliferation and differentiation in vitro","volume":"8","author":"Agresti","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cne.20991","article-title":"Development of microglia in the cerebral white matter of the human fetus and infant","volume":"497","author":"Billiards","year":"2006","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0020","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","article-title":"Erythropoietin crosses the blood\u2013brain barrier to protect against experimental brain injury","volume":"97","author":"Brines","year":"2000","journal-title":"Proc. Natl Acad. Sci."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jnen\/62.3.228","article-title":"The pleiotropic effects of erythropoietin in the central nervous system","volume":"62","author":"Buemi","year":"2003","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0030","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/jnr.20118","article-title":"Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis","volume":"76","author":"Buntinx","year":"2004","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0035","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1111\/j.1742-4658.2005.04864.x","article-title":"Poly (ADP-ribose). The most elaborate metabolite of NAD+","volume":"272","author":"Burkle","year":"2005","journal-title":"FEBS J."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0040","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1471-4159.2003.01684.x","article-title":"Poly (ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders","volume":"85","author":"Chiarugi","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neulet.2004.01.068","article-title":"Erythropoietin receptor is expressed on adult rat dopaminergic neurons and erythropoietin is neurotrophic in cultured dopaminergic neuroblasts","volume":"359","author":"Csete","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mrdd.10005","article-title":"Perinatal infection, fetal inflammatory response, white matter damage, and cognitive limitations in children born preterm","volume":"8","author":"Dammann","year":"2002","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"issue":"6","key":"10.1016\/j.expneurol.2011.04.021_bb0055","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrneurol.2010.53","article-title":"Neurobiology of injury to the developing brain","volume":"6","author":"Deng","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0060","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/archneur.65.10.1291","article-title":"Progress in periventricular leukomalacia","volume":"65","author":"Deng","year":"2008","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0065","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1523\/JNEUROSCI.20-24-09235.2000","article-title":"NBQX Attenuates excitotoxic injury in developing white matter","volume":"20","author":"Follett","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0070","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1523\/JNEUROSCI.0477-04.2004","article-title":"Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate","volume":"24","author":"Follett","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0075","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/01.STR.26.4.627","article-title":"Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation","volume":"26","author":"Garcia","year":"1995","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mrdd.10008","article-title":"Intrauterine infection and prematurity","volume":"8","author":"Goncalves","year":"2002","journal-title":"Ment. Retard. Dev. Disabil. Res. Rev."},{"issue":"4\u20135","key":"10.1016\/j.expneurol.2011.04.021_bb0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000105473","article-title":"Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke","volume":"29","author":"Gonzalez","year":"2007","journal-title":"Dev. Neurosci."},{"issue":"5","key":"10.1016\/j.expneurol.2011.04.021_bb0090","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000232558","article-title":"Erythropoietin sustains cognitive function and brain volume after neonatal stroke","volume":"31","author":"Gonzalez","year":"2009","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dnp.2007.20.5.1120219","article-title":"The role of erythropoietin in neuroprotection: therapeutic perspectives","volume":"20","author":"Grasso","year":"2007","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0100","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/01.STR.0000250742.61241.79","article-title":"Use of a poly (ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion","volume":"38","author":"Hamby","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0105","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.dnarep.2004.06.002","article-title":"PARP-1, PARP-2 and ATM in the DNA damage response: functional synergy in mouse development","volume":"3","author":"Huber","year":"2004","journal-title":"DNA Repair"},{"issue":"10","key":"10.1016\/j.expneurol.2011.04.021_bb0110","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1161\/STROKEAHA.107.483008","article-title":"Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia\/ischemia in rats","volume":"38","author":"Iwai","year":"2007","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.expneurol.2011.04.021_bb0115","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/STROKEAHA.109.570325","article-title":"Enhanced oligodendrogenesis and recovery of neurological function by erythropoietin after neonatal hypoxic\/ischemic brain injury","volume":"41","author":"Iwai","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrd1718","article-title":"Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors","volume":"4","author":"Jagtap","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0125","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.4049\/jimmunol.174.4.2288","article-title":"Poly (ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death","volume":"174","author":"Kauppinen","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0130","series-title":"Arch Dis Child Fetal Neonatal Ed","first-page":"153","article-title":"Pathogenesis of cerebral white matter injury of prematurity","author":"Khwaja","year":"2008"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0135","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","article-title":"Microglia: a sensor for pathological events in the CNS","volume":"19","author":"Kreutzberg","year":"1996","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.1098313","article-title":"Derivatives of erythropoietin that are tissue protective but not erythropoietic","volume":"305","author":"Leist","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1089\/neu.2009.1188","article-title":"Effect of acute poly(ADP-ribose) polymerase inhibition by 3-AB on blood\u2013brain barrier permeability and edema formation after focal traumatic brain injury in rats","volume":"27","author":"Lescot","year":"2010","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0155","doi-asserted-by":"crossref","first-page":"9936","DOI":"10.1073\/pnas.0502552102","article-title":"Peroxynitrite generated by inducible nitric oxide synthase and NADPH oxidase mediates microglial toxicity to oligodendrocytes","volume":"102","author":"Li","year":"2005","journal-title":"Proc. Natl Acad. Sci."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0160","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1471-4159.2010.06667.x","article-title":"Contributions of poly(ADP-ribose) polymerase-1 and -2 to nuclear translocation of apoptosis-inducing factor and injury from focal cerebral ischemia","volume":"113","author":"Li","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0165","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.clineuro.2007.05.013","article-title":"The role of erythropoietin in central and peripheral nerve injury","volume":"109","author":"Lykissas","year":"2007","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0170","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3171\/JNS-07\/08\/0392","article-title":"Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin","volume":"107","author":"Mahmood","year":"2007","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0175","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1460-9568.1996.tb01252.x","article-title":"Erythropoietin gene expression in human, monkey and murine brain","volume":"8","author":"Marti","year":"1996","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0180","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1542\/peds.2007-3753","article-title":"Annual summary of vital statistics: 2006","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.expneurol.2011.04.021_bb0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/MOP.0b013e328336eb57","article-title":"Erythropoietin for infants with hypoxic\u2013ischemic encephalopathy","volume":"22","author":"McPherson","year":"2010","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1191\/1078155205jp162oa","article-title":"Erythropoietin and neuroprotection: a therapeutic perspective","volume":"11","author":"Milano","year":"2005","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0195","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.expneurol.2006.09.026","article-title":"Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures","volume":"204","author":"Montero","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0200","doi-asserted-by":"crossref","first-page":"42774","DOI":"10.1074\/jbc.M407923200","article-title":"Critical role of the automodification of poly (ADP-ribose) polymerase-1 in nuclear factor-kappaB-dependent gene expression in primary cultured mouse glial cells","volume":"279","author":"Nakajima","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0205","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.4049\/jimmunol.173.6.3916","article-title":"Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs","volume":"173","author":"Olson","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0210","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/jnr.20450","article-title":"Effects of tumor necrosis factor-alpha on developing optic nerve oligodendrocytes in culture","volume":"80","author":"Pang","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0215","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(07)60030-0","article-title":"Trends in cerebral palsy among infants of very low birth weight (<1500g) or born prematurely (<32weeks) in 16 European centres: a database study","volume":"369","author":"Platt","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0220","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1126\/science.282.5396.2085","article-title":"Defective LPS signaling in C3H\/HeJ and C57BL\/10ScCr mice: mutations in Tlr4 gene","volume":"282","author":"Poltorak","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0225","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1084\/jem.189.4.615","article-title":"Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4)","volume":"189","author":"Qureshi","year":"1999","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.expneurol.2011.04.021_bb0230","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/NEN.0b013e3181d27138","article-title":"Erythropoietin is neuroprotective in a preterm ovine model of endotoxin-induced brain injury","volume":"69","author":"Rees","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0235","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0889-1591(02)00055-7","article-title":"Molecular insights on the cerebral innate immune system","volume":"17","author":"Rivest","year":"2003","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0240","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2169\/internalmedicine.42.142","article-title":"Pleiotropic functions of erythropoietin","volume":"42","author":"Sasaki","year":"2003","journal-title":"Intern. Med."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0245","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.21359","article-title":"Arrested oligodendrocyte lineage maturation in chronic perinatal white matter injury","volume":"63","author":"Segovia","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0255","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0968-0004(00)01780-1","article-title":"The world according to PARP","volume":"26","author":"Smith","year":"2001","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0260","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/17135","article-title":"Molecular characterization of mitochondrial apoptosis-inducing factor","volume":"397","author":"Susin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0265","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0006-8993(01)03311-X","article-title":"Effects of neonatal hypoxic\u2013ischemic brain injury on skilled motor tasks and brainstem function in adult rats","volume":"926","author":"Tomimatsu","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0270","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ncb1201-1035","article-title":"Regulation of microglial expression of integrins by poly (ADP-ribose) polymerase-1","volume":"3","author":"Ullrich","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0275","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1096\/fj.00-0540fje","article-title":"Turnover of oxidatively damaged nuclear proteins in BV-2 microglial cells is linked to their activation state by poly-ADP-ribose polymerase","volume":"15","author":"Ullrich","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0280","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainresrev.2008.04.007","article-title":"Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia\/ischemia","volume":"59","author":"Van der Kooij","year":"2008","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0285","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/brain\/awp337","article-title":"Inhibiting poly (ADP-ribose) polymerase: a potential therapy against oligodendrocyte death","volume":"133","author":"Veto","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0290","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20021067","article-title":"Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis","volume":"198","author":"Villa","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0295","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.jcbfm.9600370","article-title":"Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives","volume":"27","author":"Villa","year":"2007","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0300","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/pr.54.3.375","article-title":"The therapeutic potential of poly (ADP-ribose) polymerase inhibitors","volume":"54","author":"Vir\u00e1g","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0305","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1203\/00006450-200111000-00003","article-title":"Neurobiology of periventricular leukomalacia in the premature infant","volume":"50","author":"Volpe","year":"2001","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0310","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1542\/peds.112.1.176","article-title":"Cerebral white matter injury of the premature infant \u2014 more common than you think","volume":"112","author":"Volpe","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0315","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1542\/peds.2005-0191","article-title":"Encephalopathy of prematurity includes neuronal abnormalities","volume":"116","author":"Volpe","year":"2005","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.expneurol.2011.04.021_bb0320","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1474-4422(08)70294-1","article-title":"Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances","volume":"8","author":"Volpe","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0325","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/01.STR.0000132196.49028.a4","article-title":"Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats","volume":"35","author":"Wang","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0330","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/sj.bjp.0707285","article-title":"Postischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia","volume":"151","author":"Wang","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0335","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/jpet.105.094391","article-title":"Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats","volume":"317","author":"Wei","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0340","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/nsb836","article-title":"DNA binding is required for the apoptogenic action of apoptosis inducing factor","volume":"9","author":"Ye","year":"2002","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.expneurol.2011.04.021_bb0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1126\/science.1072221","article-title":"Mediation of poly (ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor","volume":"297","author":"Yu","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2011.04.021_bb0350","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.nbd.2003.08.008","article-title":"Poly (ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity","volume":"14","author":"Yu","year":"2003","journal-title":"Neurobiol. Dis."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448861100152X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448861100152X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:45:59Z","timestamp":1762148759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448861100152X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S001448861100152X"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2011.04.021","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2011.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}